Cancer Research The Future of Cancer Research: Science and Patient Impact Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 586-589, February 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Lieshout, E. M. M.
Right arrow Articles by Peters, W. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Lieshout, E. M. M.
Right arrow Articles by Peters, W. H. M.
[Cancer Research 59, 586-589, February 1, 1999]
© 1999 American Association for Cancer Research

Carcinogenesis

Polymorphic Expression of the Glutathione Polymorphic Expression of the Glutathione S-Transferase P1 Gene and Its Susceptibility to Barrett’s Esophagus and Esophageal Carcinoma1

Esther M. M. van Lieshout, Hennie M. J. Roelofs, Simone Dekker, Chris J. J. Mulder, Theo Wobbes, Jan B. M. J. Jansen and Wilbert H. M. Peters2

Departments of Gastroenterology [E. M. M. v. L., H. M. J. R., S. D., J. B. M. J. J., W. H. M. P.] and Surgery [T. W.], University Hospital St. Radboud, 6500 HB Nijmegen; and Department of Gastroenterology, Rijnstate Hospital, 6800TA Arnhem [C. J. J. M.], the Netherlands


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Factors determining individual susceptibility to esophageal cancer or premalignant Barrett’s epithelium are still largely unclear. An imbalance between phase I drug metabolism [e.g., cytochrome P450 (CYP)] and phase II detoxification [e.g., glutathione S-transferase (GST)] may contribute to the development of these diseases. Polymorphic variants in the CYPIA1 gene were described leading to increased levels of bioactive compounds, whereas polymorphisms in GST genes often resulted in impaired detoxification. We studied the frequencies of polymorphic variants in CYPIA1, GSTP1, GSTT1, and GSTM1 genes in 98 patients with Barrett’s epithelium and 34 patients with esophageal cancer. The results were compared with those obtained from 247 healthy blood donors. DNA was extracted, and PCR-RFLP methods were used to detect genetic polymorphisms. {Psi}2 analysis, Spearman rank correlation, and Wilcoxon rank sum tests were used for statistical evaluation. Polymorphisms in CYPIA1, GSTM1, and GSTT1 occurred at an equal frequency in patients and controls. Occurrence of the polymorphic GSTP1b variant in the GSTP1 gene resulted in a significantly lower GST enzyme activity (P < 0.05), and GSTP1b was found significantly more often in patients with Barrett’s epithelium (70%; P < 0.001) and patients with esophageal adenocarcinoma (76%; P = 0.005), as compared to healthy blood donors (41%). In conclusion, presence of the GSTP1b allele leads to lower GST enzyme activity levels and, consequently, impaired detoxification. This most important esophageal GST isoform may, therefore, contribute to the development of Barrett’s epithelium and adenocarcinoma.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Barrett’s esophagus is a pathological condition in which stratified squamous epithelium of the esophagus is replaced by columnar epithelium (1) . Compared to the general population, patients with Barrett’s esophagus have a 30–125-fold increased risk of developing esophageal adenocarcinoma (2, 3, 4) , and therefore, Barrett’s esophagus is considered to be a premalignant condition. The prevalence of esophageal adenocarcinoma is increasing rapidly, and its annual 10% rate of increase exceeds that of all other cancers (5) .

The reason for this rapid increase in adenocarcinoma of the esophagus is unknown; however, a large proportion of human cancers are related to environmental or dietary chemical compounds, either synthetic or naturally occurring (6 , 7) . Many of those chemical structures are metabolically activated to forms that have deleterious effects on organisms (8) , and this metabolic activation is an obligatory step in the initiation of many human cancers. CYP3 isoenzymes play a major role in the oxidation of chemical compounds, often resulting in the formation of highly reactive compounds that are the ultimate carcinogens (9 , 10) . CYP1A1 may be involved in the initiation of lung cancer and other smoking related cancers because it is able to generate benzo[a]pyrene-derived mutagens in cigarette smoke (11, 12, 13, 14) . Two relevant genetic polymorphisms have been demonstrated in the CYPIA1 gene: in the 3' flanking region, a T to C substitution alters protein folding, whereas an Ile to Val substitution may occur in exon 7 (15) . Both substitutions result in the enhancement of ethoxyresorufin-O-deethylase enzyme activity (16 , 17) and may contribute to an altered susceptibility to chemical carcinogens.

Human cytosolic GSTs are a family of dimeric biotransformation enzymes comprised of the four main classes; {alpha}, µ, {pi}, and {theta} (18) . They catalyze the binding of a large variety of electrophiles to the sulfydryl group of glutathione, are involved in the detoxification of (oxygen) radicals, and have a main function in the binding and transport of a wide variety of harmful compounds. GSTs have a considerably important role in the detoxification of carcinogens (18) . GSTs are present in many species and tissues and also in relatively large amounts in the epithelial tissues of the human gastrointestinal tract (19, 20, 21) . In normal esophageal epithelium, GSTP1-1 is, by far, the most important GST isoform present, at least in a quantitative sense (21) . A significant negative correlation was demonstrated between GST enzyme activity and tumor incidence in the mucosa along the human gastrointestinal tract, suggesting the importance of GSTs in tumor prevention (21) . GSTM1 and GSTT1 null genotypes have been reported to enhance the risk of developing gastric, colorectal, or lung cancer (18 , 22, 23, 24, 25, 26) , although other studies did not show such a genetic predisposition (27, 28, 29) . An Ile to Val substitution in the GSTP1 gene (GSTP1b variant) was found more often in patients with bladder and testicular cancer (30) .

Here, we studied the occurrence of genetic polymorphisms in the CYPIA1, GSTP1, GSTM1, and GSTT1 genes in Caucasian controls and patients with Barrett’s epithelium or esophageal adenocarcinoma or squamous cell carcinoma.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
mtexf}Ninety-eight patients with Barrett’s esophagus (all Caucasian; 61 males and 37 females; mean age + SE, 61 ± 2 years; age range, 25–93 years) were included in this study during a 4-year period. Biopsies were collected from both normal esophageal (three biopsies) and Barrett’s epithelium (three biopsies) at routine endoscopic inspection. Barrett’s epithelia were of the intestinal, gastric-fundic, and junctional types in 95, 2, and 1 cases, respectively. Surgical specimens were obtained from patients with adenocarcinoma (all Caucasian; n = 21, 18 males and 3 females; mean age + SE, 64 ± 2 years; age range, 43–74 years) and squamous cell carcinoma (all Caucasian; n = 13, 9 males and 4 females; mean age + SE, 54 + 3 years; age range, 32–70 years). In all cases, diagnosis was confirmed by a pathologist. All tissues were immediately frozen in liquid nitrogen and stored at-80°C until use. Blood samples were collected from 247 healthy volunteers (Caucasians; 98 males and 149 females; mean age + SE, 52 + 2 years; age range, 18–78 years) by venipuncture in sterile siliconized EDTA K3 (15%) 4-ml Vacutainer tubes (Becton Dickinson, San Jose, CA). Whole blood was stored at -20°C until use. The investigations were approved by the local ethical committee on human experimentation.

Genomic DNA was extracted from tissue using phenol, chloroform, and isoamylalcohol according to Maniatis et al. (31) . Genomic DNA was isolated from whole blood using the Wizard genomic DNA purification kit, according to the instructions of the manufacturer (Promega, Madison, WI). Genetic polymorphisms were detected by PCR-RFLP. For detection of the null polymorphisms in GSTM1 (primer set G2 and G3; see Ref. 29 ) and GSTT1 (primer set T1 and T2; see Ref. 32 ), one primer was situated in the deleted area. For studying the genetic polymorphism in GSTP1, a primer set (105F and 105R) was designed so that the presence of the rare G allele (Val) resulted in the appearance of an Alw26I restriction enzyme site (30) . Genetic polymorphism in exon 7 of CYPIA1 was detected using the primer set CYPIA1/1 and CYPIA1/2, and the presence of the rare G allele (Val) resulted in loss of an NcoI restriction enzyme site (15) . For the polymorphism in the 3' flanking region of CYPIA1, primer set C44 and C47 was designed so that the presence of the rare C nucleotide resulted in the appearance of an MspI restriction enzyme site (15) . All primers were synthesized by Pharmacia Biotech (Roosendaal, the Netherlands). All chemicals needed for PCR were purchased from Promega.

Cytosolic fractions from normal squamous mucosa were prepared, and protein concentration and GST enzyme activity toward 1-chloro-2,4-dinitrobenzene were measured essentially as described previously (21) .

The statistical significance of differences for individual and combined polymorphisms between different groups was tested with {chi}2 analysis with Yates correction in 2 x 2 (GSTM1 and GSTT1) or 2 x 3 (GSTP1 and CYPIA1) contingency tables. Spearman rank correlation test was used for assessing the association between GST enzyme activity and GSTP1 polymorphism. Wilcoxon rank sum test was used to compare GST enzyme activity in the GSTP1a-1a group with that in the GSTP1a-1b and GSTP1b-1b groups, respectively.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Results of the analysis of genetic polymorphisms in CYPIA1, GSTP1, GSTM1, and GSTT1 genes are presented in Table 1Citation . Presence of rare alleles in exon 7 or the 3' flanking region of CYPIA1 was found equally often in patients with Barrett’s esophagus, adenocarcinoma, and squamous cell carcinoma, as compared to the control population. GSTM1 and GSTT1 null genotypes were found in 52 and 20% of controls, respectively, and these frequencies were not different from those in the patient populations studied. In controls, the above-mentioned polymorphisms did not differ between males and females.


View this table:
[in this window]
[in a new window]
  		Table 1 Frequencies of polymorphisms in CYPIA1, GSTP1, GSTM1, and GSTT1 genes in controls and patients with Barrett’s esophagus, adenocarcinoma, and squamous cell carcinoma of the esophagusa

 
The Ile to Val substitution in GSTP1 (GSTP1b variant) was found significantly more often in patients with Barrett’s esophagus (59% heterozygous and 11% homozygous; {Psi}2 = 25.14, P < 0.0001) and adenocarcinoma (71% heterozygous and 5% homozygous; {Psi}2 = 10.53, P = 0.005) as compared to controls (36% heterozygous and 5% homozygous). No difference was found between controls and patients with squamous cell carcinoma or between patients with adenocarcinoma and Barrett’s esophagus. Occurrence of the GSTP1b genotype was significantly correlated with GST enzyme activity in normal esophageal mucosa (Table 2)Citation , as studied by the Spearman rank correlation test: Rs = -0.21 (95% confidence interval, -0.38–0.03; P = 0.02). GST enzyme activity in normal esophagus of Ile/Val and Val/Val subjects (GSTP1a-1b and GSTP1b-1b, respectively) was significantly lower than the activities in normal esophageal tissue of GSTP1a-1a (wild-type) subjects (both P < 0.05, Wilcoxon rank sum test).


View this table:
[in this window]
[in a new window]
  		Table 2 Association between GSTP1 genotype and GST enzyme activity in normal esophageal mucosa from patients with Barrett’s epitheliuma

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Individual susceptibility to gastrointestinal cancers may be partly due to genetic differences in the metabolic balance between activation and detoxification of (pro)carcinogens. The activation of procarcinogens to carcinogens is an obligatory step in initiation of human carcinogenesis (8, 9, 10) . Nakajima et al. (33) demonstrated that carcinogens can be formed or inactivated in human esophageal epithelium by enzymatic activity of CYPIA1, GST {alpha}, GST µ, or GST {pi}. Genetic polymorphisms in the 3' flanking region or in exon 7 of CYPIA1, both leading to a more active enzyme, are found equally often in patients with Barrett’s epithelium, adenocarcinoma, or squamous cell carcinoma of the esophagus as compared to controls. This points toward a lack of association of CYPIA1 genotype and development of Barrett’s esophagus or esophageal cancer. Previously, Murray et al. (34) found no difference in the expression levels of CYPIA1 protein between noncancer and cancerous tissues of the esophagus. Similar to our results, Morita et al. (35) did not find an association between CYPIA1 genotype and squamous cell carcinoma of the esophagus (53 patients versus 132 controls) in the Japanese population. Nimura et al. (36) showed that the CYPIA1/exon 7 polymorphism was related to esophageal carcinoma in smokers only (89 patients versus 137 controls).

GSTs are involved in the detoxification of a wide variety of chemical carcinogens, and four main subclasses have been identified in humans (18) . Approximately 50% of Caucasians lack a functional GSTM1 gene (37 , 38) . Previous studies have shown that the GSTM1 gene deletion is more common among patients with colorectal cancer (22 , 24 , 27 , 39) , squamous cell carcinoma of the lung (25) , and other lung cancers (23) , although results are conflicting in other studies on lung cancer (28 , 29) . The GSTT1 null genotype has been correlated with increased risk of colorectal cancer (24 , 26) , although in another study (27) , such a relationship was not found. In our study, the GSTM1 and GSTT1 null frequencies did not differ between patients and controls, which indicates that a lack of these enzymes is not crucial for development of Barrett’s esophagus or esophageal carcinoma. This agrees well with data of Morita et al. (35) , which showed no association between GSTM1 deletion and occurrence of squamous cell carcinoma of the esophagus. Nimura et al. (36) , however, found an association between GSTM1 null genotype and esophageal carcinoma in smokers. Overall, it may be concluded that GSTM1 or GSTT1 null individuals may be more susceptible to certain types of cancer, although lifestyle and dietary habits, without doubt, are of great importance in this respect.

A bp substitution at nucleotide 313 of the GSTP1 gene (so-called GSTP1b variant) was found significantly more often in patients with Barrett’s esophagus or esophageal adenocarcinoma, which may point toward a genetic predisposition to these diseases. No higher rates of GSTP1b alleles were found in patients with squamous cell carcinoma, which is in agreement with the fact that esophageal adenocarcinomas but not squamous cell carcinomas often develop from Barrett’s epithelium. Harries et al. (30) demonstrated an association between occurrence of the GSTP1b polymorphism and susceptibility to bladder or testicular cancer, whereas no such association was observed in patients with breast or colon cancer. In the control population from the United Kingdom (n = 155), a very similar percentage of wild-type gene (GSTP1a-1a) was found, as compared to our Dutch controls (51 versus 59%, respectively).

In normal esophageal mucosa from patients with Barrett’s esophagus, we were able to demonstrate that presence of a GSTP1b allele significantly correlated with a lower GST enzyme activity. A similar association was recently found in normal lung tissue from patients with lung cancer (40) . By expressing the GSTP1b-1b variant in Escherichia coli, Ali Osman et al. (41) demonstrated a lower affinity for 1-chloro-2,4-dinitrobenzene but not for glutathione, resulting in a reduced Vmax of this modified enzyme. In a quantitative sense, GSTP1-1 is by far the most important GST isoform in normal esophageal mucosa (21) . The observed reduction in GST enzyme activity associated with the occurrence of GSTP1b variants in normal esophageal tissue of patients with Barrett’s esophagus may imply that these patients have a decreased capacity to detoxify carcinogens, resulting in an increased risk for development of premalignant and malignant diseases.

In summary, we found no evidence for a possible genetic predisposition to Barrett’s esophagus or esophageal carcinoma due to genetic polymorphisms in CYPIA1, GSTM1, or GSTT1. However, higher frequencies of the GSTP1b gene variant were present in patients with Barrett’s esophagus and adenocarcinoma, with concomitant reduction of GST enzyme activity in normal esophageal epithelium. As a consequence of this partially deficient GST system in these patients, an impaired detoxification of carcinogens may exist, resulting in an enhanced cancer risk.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Dutch Cancer Society Grant 94-715. Back

2 To whom requests for reprints should be addressed, at Department of Gastroenterology, University Hospital St. Radboud, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. Phone: 31-24-36-15-123; Fax: 31-24-35-40-103. Back

3 The abbreviations used are: CYP, cytochrome P450; GST, glutathione S-transferase. Back

Received 7/17/98. Accepted 12/ 2/98.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Spechler S. J., Goyal R. K. Barrett’s esophagus. N. Engl. J. Med., 315: 362-371, 1987.[Medline]
  2. Spechler S. J., Robbins A. H., Bloomfield Rubens H., Vincent M. E., Heeren T., Doos W. G., Colton T., Schimmel E. M. Adenocarcinoma, and Barrett’s esophagus. An overrated risk?. Gastroenterology, 96: 1249-1256, 1989.[Medline]
  3. Hameeteman W., Tytgat G. N. J., Houthoff H. J., van den Tweel J. G. Barrett’s esophagus: development of dysplasia and adenocarcinoma. Gastroenterology, 96: 1249-1256, 1989.
  4. Pera M., Cameron A., Trastek V. F., Carpenter H. A., Zinsmeister A. R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology, 104: 510-513, 1993.[Medline]
  5. Blot W. J., Devese S. S., Kneller R. W., Fraumeni J. F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J. Am. Med. Assoc., 265: 1287-1289, 1991.[Abstract]
  6. Nagao M., Sugimura T., Matsushima T. Environmental mutagens and carcinogens. Annu. Rev. Genet., 12: 117-159, 1978.[Medline]
  7. Doll R., Peto R. The Causes of Cancer1256-1260, Oxford University Press New York 1981.
  8. Heidelberger C. Chemical carcinogenesis. Annu. Rev. Biochem., 44: 79-121, 1975.[Medline]
  9. Guengerich F. P. Roles of cytochrome P-450 in chemical carcinogenesis and cancer chemotherapy. Cancer. Res., 48: 2946-2954, 1988.[Free Full Text]
  10. Conney A. H. Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G. H. A. Clowes Memorial Lecture. Cancer Res., 42: 4875-4917, 1982.[Free Full Text]
  11. Aoyama T., Gonzalez F., Gelboin H. V. Mutagen activation by cDNA-expressed P(1)450, P(3)450, and P450a. Mol. Carcinog., 1: 253-259, 1989.[Medline]
  12. McManus M. E., Burgess W. M., Veronese M. E., Huggett A., Quattrochi L. C., Tuckey R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome P-450. Cancer Res., 50: 3367-3376, 1990.[Abstract/Free Full Text]
  13. Kawajiri K., Nakachi K., Imai K., Yoshi A., Shinoda N., Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett., 263: 131-133, 1990.[Medline]
  14. Nakachi K., Imai K., Hayashi S., Watanabe J., Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res., 51: 5177-5180, 1991.[Abstract/Free Full Text]
  15. Shields P. G., Bowman E. D., Harrington A. M., Doan V. T., Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res., 53: 3486-3492, 1993.[Abstract/Free Full Text]
  16. Li M. T., Bertazzi P. A., Shields P. G., Clark G., Lucier G. W., Garte S. J., Cosma G., Caporaso N. E. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics, 4: 242-246, 1994.[Medline]
  17. Cosma G., Crofts F., Taioli E., Tniolo P., Garte S. Relationship between genotype and function of the human CYP1A1 gene. J. Toxicol. Environ. Health, 40: 309-316, 1993.[Medline]
  18. Hayes J. D., Pulford D. J. The glutathione S-transferase supergene family: regulation of GST and contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit. Rev. Biochem. Mol. Biol., 31: 445-600, 1995.
  19. Peters W. H. M., Kock L., Nagengast F. M., Kremers P. G. Biotransformation enzymes in human intestine: critical levels in the colon?. Gut, 32: 408-412, 1991.[Abstract/Free Full Text]
  20. Peters W. H. M., Nagengast F. M., Van Tongeren J. H. M. Glutathione S-transferase, cytochrome P450, and uridine 5'-diphosphate-glucuronosyltransferase in human small intestine and liver. Gastroenterology, 96: 783-789, 1989.[Medline]
  21. Peters W. H. M., Roelofs H. M. J., Hectors M. P. C., Nagengast F. M., Jansen J. B. M. J. Glutathione and glutathione S-transferases in Barrett’s epithelium. Br. J. Cancer, 67: 1413-1417, 1993.[Medline]
  22. Strange R. C., Matheroo B., Faulder G. C., Jones P., Cotton W., Elder J. B., Deakin M. The human glutathione S-transferases: a case control study of the incidence of the GST1 0 phenotype in patients with adenocarcinoma. Carcinogenesis (Lond.), 12: 25-28, 1991.[Abstract/Free Full Text]
  23. Seidegard J., Pero R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isoenzymes of glutathione S-transferase (class µ) as a marker for susceptibility to lung cancer: a follow up study. Carcinogenesis (Lond.), 11: 33-36, 1990.[Abstract/Free Full Text]
  24. Chevenix-Trench G., Young J., Coggan M., Board P. Glutathione S-transferase M1, and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis (Lond.), 16: 1655-1657, 1995.[Abstract/Free Full Text]
  25. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Vainio H. The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis (Lond.), 14: 1479-1481, 1991.[Abstract/Free Full Text]
  26. Deakin M., Elder J., Hendrickse C., Peckham D., Baldwin D., Pantin C., Wild N., Leopard P., Bell D. A., Jones P., Duncan H., Brannigan K., Alldersea J., Fryer A. A., Strange R. C. Glutathione S-transferase GSTT1 genotype and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis (Lond.), 17: 881-884, 1996.[Abstract/Free Full Text]
  27. Katoh T., Nagata N., Kuroda Y., Itoh H., Kawahara A., Kuroki N., Ookuma R., Bell D. A. Glutathione S-transferase M1 (GSTM1), and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis (Lond.), 17: 1855-1859, 1996.[Abstract/Free Full Text]
  28. Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J. Natl. Cancer Inst. (Bethesda), 84: 414-422, 1992.[Abstract/Free Full Text]
  29. Brockmuller J., Kerb R., Drakoulis N., Nitz M., Roots I. Genotype and phenotype of glutathione S-transferase class µ isoenzymes µ and {pi}{psi} in lung cancer patients and controls. Cancer Res., 53: 1004-1011, 1993.[Abstract/Free Full Text]
  30. Harries L. W., Stubbins M. J., Forman D., Howard G. C., Wolf C. R. Identification of genetic polymorphisms at the glutathione S-transferase {pi} locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (Lond.), 18: 641-644, 1997.[Abstract/Free Full Text]
  31. Maniatis T., Fritsch E. F., Sambrook J. Molecular cloning: A Laboratory Manual280-281, Cold Spring Harbor Laboratory Cold Spring Harbor 1982.
  32. Pemble S., Schroeder K. R., Spencer S. R., Meyer D. J., Hallier E., Bolt H. M., Ketterer B., Taylor J. B. Human glutathione S-transferase {theta} (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J., 300: 271-276, 1994.
  33. Nakajima T., Wang R. S., Nimura Y., Pin Y. M., He M., Vainio H., Murayama T., Iika F. Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. Carcinogenesis (Lond.), 17: 1477-1481, 1996.[Abstract/Free Full Text]
  34. Murray G. I., Shaw D., Weaver R. J., McKay J. A., Ewen S. W., Melvin W. T., Burke M. D. Cytochrome P450 expression in oesophageal cancer. Gut, 35: 599-603, 1994.[Abstract/Free Full Text]
  35. Morita S., Yano M., Sjiozaki H., Tsujinaka T., Ebisui C., Morimoto T., Kishibuti M., Fujita J., Ogawa A., Taniguchi M., Inoue M., Tamura S., Yamazaki K., Kikkawa S., Monden M. CYP1A1,CYP2E1 and GSTM1 polymorphisms are not associated with susceptibility to squamous-cell carcinoma of the esophagus. Int. J. Cancer, 71: 192-195, 1997.[Medline]
  36. Nimura Y., Yokoyama S., Fujimori M., Aoki T., Adachi W., He M., Ping Y. M., Iida F. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer (Phila.), 80: 852-857, 1997.[Medline]
  37. Board P. G. Biochemical genetics of glutathione S-transferase in man. Am. J. Hum. Genet., 33: 36-43, 1981.[Medline]
  38. Seidegard J., Vorachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathione transferase active of trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA, 85: 7293-7297, 1988.[Abstract/Free Full Text]
  39. Zhong S., Wyllie A. H., Barnes D., Wolf C. R., Spurne N. K. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis (Lond.), 14: 1821-1824, 1993.[Abstract/Free Full Text]
  40. Watson M. A., Stewart R. K., Smith G. B. J., Massey T. E., Bell D. A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis (Lond.), 19: 275-280, 1998.[Abstract/Free Full Text]
  41. Ali Osman F., Akande O., Antoun G., Mao L. X., Buolamwin J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase {pi} gene variants. Evidence for different catalytic activity of the encoded proteins. J. Biol. Chem., 272: 10004-10012, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
A. Rossini, D.C.M. Rapozo, S.C. Soares Lima, D.P. Guimaraes, M.A. Ferreira, R. Teixeira, C.D.P. Kruel, S.G.S. Barros, N.A. Andreollo, R. Acatauassu, et al.
Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population
Carcinogenesis, December 1, 2007; 28(12): 2537 - 2542.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. J. Murphy, A. E. Hughes, C. C. Patterson, L. A. Anderson, R.G.P. Watson, B. T. Johnston, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray
A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett's esophagus and esophageal adenocarcinoma
Carcinogenesis, June 1, 2007; 28(6): 1323 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
R C Fitzgerald
Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.
Gut, December 1, 2006; 55(12): 1810 - 1820.
[Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
R. A. KAVISHE, J. B. KOENDERINK, M. B.B. MCCALL, W. H.M. PETERS, B. MULDER, C. C. HERMSEN, R. W. SAUERWEIN, F. G.M. RUSSEL, and A. J.A.M. VAN DER VEN
SEVERE PLASMODIUM FALCIPARUM MALARIA IN CAMEROON: ASSOCIATED WITH THE GLUTATHIONE S-TRANSFERASE M1 NULL GENOTYPE
Am J Trop Med Hyg, November 1, 2006; 75(5): 827 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Cai, L.-N. Mu, H. Lu, Q.-Y. Lu, N.-C. Y. You, S.-Z. Yu, A. D. Le, J. Zhao, X.-F. Zhou, J. Marshall, et al.
Dietary Selenium Intake and Genetic Polymorphisms of the GSTP1 and p53 Genes on the Risk of Esophageal Squamous Cell Carcinoma.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 294 - 300.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen
Association of GSTP1 Polymorphism and Survival for Esophageal Cancer
Clin. Cancer Res., July 1, 2005; 11(13): 4749 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
B Yucesoy, V J Johnson, M L Kashon, K Fluharty, V Vallyathan, and M I Luster
Lack of association between antioxidant gene polymorphisms and progressive massive fibrosis in coal miners
Thorax, June 1, 2005; 60(6): 492 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
L. F. Masson, L. Sharp, S. C. Cotton, and J. Little
Cytochrome P-450 1A1 Gene Polymorphisms and Risk of Breast Cancer: A HuGE Review
Am. J. Epidemiol., May 15, 2005; 161(10): 901 - 915.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Rodriguez, C. de la Roza, R. Jardi, M. Schaper, R. Vidal, and M. Miravitlles
Glutathione S-Transferase P1 and Lung Function in Patients With {alpha}1-Antitrypsin Deficiency and COPD
Chest, May 1, 2005; 127(5): 1537 - 1543.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E.M.J. van der Logt, S.M. Bergevoet, H.M.J. Roelofs, Z. van Hooijdonk, R.H.M. te Morsche, T. Wobbes, J.B. de Kok, F.M. Nagengast, and W.H.M. Peters
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk
Carcinogenesis, December 1, 2004; 25(12): 2407 - 2415.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D J de Jong, E M J van der Logt, A van Schaik, H M J Roelofs, W H M Peters, and T H J Naber
Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase
Gut, April 1, 2003; 52(4): 547 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J.-Q. He, J. Ruan, J. E. Connett, N. R. Anthonisen, P. D. Pare, and A. J. Sandford
Antioxidant Gene Polymorphisms and Susceptibility to a Rapid Decline in Lung Function in Smokers
Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 323 - 328.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. Jeronimo, G. Varzim, R. Henrique, J. Oliveira, M. J. Bento, C. Silva, C. Lopes, and D. Sidransky
I105V Polymorphism and Promoter Methylation of the GSTP1 Gene in Prostate Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., May 1, 2002; 11(5): 445 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
S. Garte, L. Gaspari, A.-K. Alexandrie, C. Ambrosone, H. Autrup, J. L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, et al.
Metabolic Gene Polymorphism Frequencies in Control Populations
Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1239 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
P. Taniere, G. Martel-Planche, D. Maurici, C. Lombard-Bohas, J.-Y. Scoazec, R. Montesano, F. Berger, and P. Hainaut
Molecular and Clinical Differences between Adenocarcinomas of the Esophagus and of the Gastric Cardia
Am. J. Pathol., January 1, 2001; 158(1): 33 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
P. L. M. ZUSTERZEEL, W. VISSER, W. H. M. PETERS, H. W. M. J. MERKUS, W. L. D. M. NELEN, and E. A. P. STEEGERS
Polymorphism in the Glutathione S-transferase P1 Gene and Risk for Preeclampsia
Obstet. Gynecol., July 1, 2000; 96(1): 50 - 54.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin
Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China
Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556.
[Abstract] [Full Text]

Home page
 ThoraxHome page
F. RODRIGUEZ-FRIAS, C. GONZALEZ, X. COSTA, F. CAMPOS, M. COTRINA, R. JARDI, M. MIRAVITLLES, R. VIDAL;, T. ISHII, S. TERAMOTO, et al.
Screening for polymorphisms in exon 5 of the glutathione S-transferase Pl gene
Thorax, June 1, 2000; 55(6): 535b - 535.
[Full Text]

Home page
 Mol Hum ReprodHome page
P. L.M. Zusterzeel, W. L.D.M. Nelen, H. M.J. Roelofs, W. H.M. Peters, H. J. Blom, and E. A.P. Steegers
Polymorphisms in biotransformation enzymes and the risk for recurrent early pregnancy loss
Mol. Hum. Reprod., May 1, 2000; 6(5): 474 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. M. Whyatt, F. P. Perera, W. Jedrychowski, R. M. Santella, S. Garte, and D. A. Bell
Association between Polycyclic Aromatic Hydrocarbon-DNA Adduct Levels in Maternal and Newborn White Blood Cells and Glutathione S-Transferase P1 and CYP1A1 Polymorphisms
Cancer Epidemiol. Biomarkers Prev., February 1, 2000; 9(2): 207 - 212.
[Abstract] [Full Text]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov
Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers
Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Lieshout, E. M. M.
Right arrow Articles by Peters, W. H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Lieshout, E. M. M.
Right arrow Articles by Peters, W. H. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online